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Antimicrobial peptides and their precursor molecules form a central part of human and mammalian innate immunity. The underlying genes
have been thoroughly investigated and compared for a considerable number of species, allowing for phylogenetic characterization. On the
phenotypical side, an ever-increasing number of very varied and distinctive influences of antimicrobial peptides on the innate immune system are
reported. The basic biophysical understanding of mammalian antimicrobial peptides, however, is still very limited. This is especially
unsatisfactory since knowledge of structural properties will greatly help in the understanding of their immunomodulatory functions. The focus of
this review article will be on LL-37, the only cathelicidin-derived antimicrobial peptide found in humans. LL-37 is a 37-residue, amphipathic,
helical peptide found throughout the body and has been shown to exhibit a broad spectrum of antimicrobial activity. It is expressed in epithelial
cells of the testis, skin, the gastrointestinal tract, and the respiratory tract, and in leukocytes such as monocytes, neutrophils, T cells, NK cells, and
B cells. It has been found to have additional defensive roles such as regulating the inflammatory response and chemo-attracting cells of the
adaptive immune system to wound or infection sites, binding and neutralizing LPS, and promoting re-epthelialization and wound closure. The
article aims to report the known biophysical facts, with an emphasis on structural evidence, and to set them into relation with insights gained on
phylogenetically related antimicrobial peptides in other species. The multitude of immuno-functional roles is only outlined. We believe that this
review will aid the future work on the biophysical, biochemical and immunological investigations of this highly intriguing molecule.
© 2006 Elsevier B.V. All rights reserved.Keywords: Antimicrobial peptide; LL-37; Cathelicidin; Solid-state NMR; Antibiotic; Membrane
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1.1. Mammalian innate immunity
During the last two decades, piece by piece, a fascinating and
still enigmatic strategy of vertebrates to deal with intruding mi-
croorganisms has been revealed. In tissues that first make contact
with intruders, antimicrobial peptides (AMPs) are released from
precursor proteins [1,2]. Their cationic and amphipathic proper-
ties make them resemble antimicrobial peptides that are excreted
by prokaryotes to kill other microorganisms. In prokaryotes,
AMPs are either synthesized in non-ribosomal pathways or
cleaved from ribosomally generated precursors. Certain mam-
malian leukocytes, called granulocytes, contain granules that hold
large amounts of AMP precursors. These precursors are cleaved
into active AMPs upon secretion into phagosomes. Thereby,
AMPs are brought into direct fatal contact with phagocytosed
microorganisms.
However, direct antimicrobial action is not the only, and
possibly not even the primary task of mammalian AMPs. This is
suggested by the fact that peptides of innate immunity suffer
losses in their antibacterial properties under serum and tissue
conditions. Instead, they seem to fill important immunomod-
ulatory roles in a complicated network of interactions between
innate and acquired immunity [3–6].
In mammals, at least two distinct groups of antimicrobial
peptides and corresponding precursors are found. Defensins
form the group with most representatives. Their instances in
human were covered in another review article by Dhople et al.
in this special issue. Cathelicidin-derived AMPs form a second
group of mammalian AMPs. Their common feature is the highly
conserved cathelin domain that complements the antimicrobial
peptide in the precursor. Some researchers, e.g., De Smet and
Contreras [7], regard histatins as a distinct third group that has
to be seen in close relationship to defensins and cathelicidins. A
recent review article examines the role of antimicrobial peptides
in the skin [8].
1.2. Cathelicidins
Cathelicidins form a distinct class of proteins present in the
innate immunity ofmammals [9,10]. Similar to defensins, they act
as precursor molecules that can release an antimicrobial peptide
after proteolytic cleavage. Their structural features clearly dis-
tinguish them from defensins. The discovery of cathelicidins
commenced after the isolation of the antimicrobial peptide Bac5
from bovine neutrophils, and the realization that they are cleaved
from inactive precursors [11–13]. Cloning of a cDNA coding forthe precursor allowed to search for the gene [14]. Surprisingly, the
search lead to the discovery of numerous genes. It was soon
realized that those genes code for a whole family of related
proteins [15].
The hallmark of the cathilicidin family of proteins is the pres-
ence of a highly conserved cathelin domain [9,16]. Cathelin was
first found in pig leukocytes and characterized as an inhibitor of
the cysteine proteinase cathepsin L, and was named after this
property [17]. Amino acid sequence comparison locates cathelin
to the cystatin superfamily of proteins [17–19], which comprises
cystatin (cysteine proteinase inhibitor), kininogen, and stefin pro-
teins [20]. The realization that the cathelin region is highly con-
served among the cathelicidins of one species, as well as among
different species, made direct genetic searches possible. For a
number of species, the genes of their cathelicidins could be suc-
cessfully located by sequence screening and cDNA-cloning,
making use of the highly conserved nature of the cathelin domain.
Once the gene is identified, evidence for the proprotein and the
derived mature AMP can be directly sought for.
The cathelicidin proteins are characterized by a highly
conserved N-terminal domain of about 100 amino acid residues.
This 14 kDa cathelin-like domain is flanked by a signal peptide
domain (approximately 30 residues long) on its N-terminus, and
by an antimicrobial peptide region on its C-terminus. Fig. 1
gives the topology of the 18-kDa human cathelicidin hCAP18
as a prototype illustration for the similar topology of all cathe-
licidins [21]. The primary translation product is called the
‘preprotein’, since it contains a signal sequence as a prelude to
the cathelicidin holo-protein. This signal peptide is cleaved off
once it has fulfilled its purpose of targeting the cathelicidin to
storage granules or to the exterior of the cell. The formation of
two disulfide-bridges finalizes post-transcriptional processing.
The cathelicidin holo-protein is then referred to as the ‘pro-
protein’, since it does not represent the active, but rather a stor-
age form. Only after cleavage of the proprotein into the cathelin
domain and the cathelicidin-derived AMP, does it unfold its
host of activities.
Cathelicidin proteins have been extensively studied in mam-
mals to date. However, cathelicidins were also recently found in
chicken [22] and three species of fish [23–25]. Especially
interesting is the case of hagfish, the oldest living member of
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ponents of adaptive immunity [26]. In hagfish, two cathelicidins
are described [25]. The presence of cathelicidins in this very
ancient species may indicate that cathelicidin genes developed
early in phylogenesis and are present in most, if not all, higher
organisms. In cattle, horse, pig, sheep, and goat, up to seven
cathelicidins are found, each being the precursor for individual
AMPs of very different structural properties. Among this multi-
tude of structurally divergent AMPs, all of the named species
have at least two α-helical AMPs derived from cathelicidin
precursors. In human, only a single cathelicidin is found. This is
in contrast to the situation for the cathelicidins of other species.
It is also contrasting the (at least) 10 human defensins. The same
situation of a single cathelicidin is found in rhesus monkey
[27,28], mouse [29], rat [30], and guinea pig [31]. All these
species are phylogenetically more closely related to human than
the species named earlier. An exception is formed by rabbit, a
further representative of rodents, in which a second cathelicidin
called p15s is found in addition to CAP18.
Both Uzzell et al. [25] and Termén et al. [30], in connection
to their studies on HFIAP and rCRAMP, respectively, per-
formed sequence alignments between the signal and cathelin
domains of their cathelicidins and all other known ones. There-
by, they could establish the phylogenetic ancestry of the cathe-
licidins. A concise graphical overview about the phylogenetic
relationships and the cathelicidins found in each species is given
by Zanetti [9]. The single 16 kDa human cathelicidin is denoted
as hCAP18. Its name was chosen because of its close rela-
tionship to the cationic antimicrobial peptide found in rabbit,
which has a molecular weight of 18 kDa and is therefore called
CAP18. The gene for hCAP18 was described by three research
groups independently [32–34]. Fig. 1 gives an overview of the
topology of the primary translation product reported by these
studies. The gene for the human cathelicidin hCAP18 is a
compact gene of 1963 bp located to chromosome 3, and is
composed of four exons [21,35]. Exons 1 to 3 code for the
signal sequence and the cathelin domain, while exon 4 codes for
the antimicrobial peptide, LL-37. Boman [3] presents the
numerous upstream control sites for transcription factors that
regulate the expression of the gene.
The cathelicidin proprotein is currently regarded as an in-
active precursor that becomes active only upon proteolytic
cleavage into cathelin domain and cathelicidin-derived AMP.
Two observations may challenge that view: uncleaved propro-
tein is present in human plasma lipoproteins [36], and holo-
proteins in rabbit granulocytes are found to have synergy with
bactericidal/permeability-increasing protein [37]. Elastin seems
to be the most common peptidase to cleave cathelicidins [38,39].
In human hCAP18, however, protease-3 cleaves the proprotein
[40]. Two research groups reported alternative processing proce-
dures. Sorensen et al. [41] found seminal hCAP18 to be cleaved
to ALL-38 by the prostate-derived protease gastricsin at vaginal
pH. Murakami et al. [42] investigated LL-37 in sweat and found
that it is further degraded by a serine-protease dependent mech-
anism to yield KR-20, RK-31, andKS-30. These fragments were
found to possess increased antimicrobial activity. The authors
conclude that further cleavage allows the organism to shift LL-37's action from signaling function towards antimicrobial effect.
A hint at more subtle properties of cathelicidin cleavage comes
from the mouse and rat cathelicidins, CRAMP and rCRAMP,
respectively [29,30]. Although very similar in structure, they are
cleaved at two different sites, resulting in AMPs of quite different
length. This makes Termén et al. [30] speculate that either two
alternative cleavage procedures may be present in one or both of
the species, or that each species has developed an individual
cleavage mechanism to respond to evolutionary pressure.
The structure of the cathelin domain freed from pig protegrin-
3 was investigated in two different studies. Sanchez et al. crys-
tallized the cathelin domain and determined its structure using
X-ray crystallography [43], while Yang et al. found a very si-
milar structure by means of NMR spectroscopy [44]. The struc-
ture consists of a four-stranded β-sheet and an α-helix
spanning one side of the β-sheet. Since the very similar pro-
tegrin-1 is known to form a β-hairpin secondary structure
[45,46], Sanchez et al. [43] speculate that in the uncleaved
proprotein this β-hairpin extends the cathelin domain's β-sheet
moiety into a six-stranded β-sheet. This model predicts the
connecting loop region (between cathelicidin and protegrin-1
domain) to be on the protein surface, and thus to be fully
accessible to the cleaving peptidase. After cleavage, the human
cathelin domain possesses antimicrobial and protease inhibitory
functions of its own [47]. However, the present contribution will
now turn to its main focus on the AMPs that are cleaved off of
the cathelin domain.
1.3. Cathelicidin-derived AMPs
In contrast to the highly conserved cathelin domain of the
cathelicidins, the derived AMPs show highly differing sequences
and secondary structures. For example, α-helical AMPs rich in
Pro, Arg or Trp (indolicidin) and cysteine-bridged AMPs (dode-
capeptide, integrins) have been reported. Gennaro and Zanetti
[16] as well as Ramanathan et al. [48] presented overviews about
the different structural classes of AMPs derived from cathelicidin
holo-proteins. The present review focuses on LL-37, the only
human cathelicidin-derived AMP. LL-37 belongs to the class of
α-helical AMPs. This seems to be the common secondary struc-
ture in all organisms where only a single cathelicidin-derived
AMP is found. LL-37 owes its name to its 37 amino acid overall
length with the two leading residues being leucines. It does not
contain any cysteine residues.
The initial report of the hCAP18/LL-37 gene [32] assumed
the 39-residue C-terminal domain (termed FALL-39) to be the
active AMP, based on the presence of a typical KR cleavage site
[33,34]. Gudmundsson et al. [35] shortly afterwards used
antibody binding to prove that LL-37, a peptide two amino
acids shorter than FALL-39, is the matured AMP. Their study
also found the peptide to be located in granulocytes. Two of the
three groups first describing the hCAP18/LL-37 gene prepared
the peptides FALL-39 and LL-37 synthetically, and showed
them to be antimicrobially active [32,33]. Larrick et al. [35]
additionally synthesized a truncated peptide with the C-ter-
minus being shortened by 5 amino acids. This truncated peptide
showed increased antimicrobial activity [33].
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compare it to the sequences of otherα-helical cathelicidin-derived
AMPs found in closely related species, i.e., species where only a
single cathelicidin is present. Therefore, we took the respective
portion of the table given in Ramanathan et al. publication [48],
and augmented it in three ways. First, we added the sequence of
rCRAMP, a cathelicidin-derived AMP only recently described
in rat, and predicted to be α-helical [30]. Moreover, we give
both contradictory sequence determinations carried out for rhe-
sus monkey [27,28]. For the sake of completeness, we also in-
cluded the sequences of cathelicidin-derived AMP recently
described in chicken [22] and three species of fish, namely
rainbow trout [23,24], atlantic salmon [24], and hagfish [25,49].
Both hagfish AMPs were predicted to be α-helical by Zanetti [9].
The resulting compilation is presented as Table 1.Table 1
A selection of cathelicidin-derived α-helical AMPs, chosen by phylogenic or
structural similarity to LL-37
Peptide Origin Amino acid sequence #AA Ref.
LL-37 Human LLGDFFRKSK–EKIGKEFKRI–
VQRIKDFLRN–LVPRTES
37 [51]
rhLL-37a Rhesus identical to LL-37 37 [27]
RL-37a Monkey RLGNFFRKVK–EKIGGGLKKV–
GQKIKDFLGN–LVPRTAS
37 [28]
CAP18 Rabbit GLRKRLRKFR–NKIKEKLKKI–
GQKIQGLLPK–LAPRTDY
37 [52]
CRAMP Mice GLLRKGGEKI–GEKLKKIGQK–
IKNFFQKLVP–QPE
33 [29]
rCRAMP Rat RFKKISRLAG–LLRKGGEKFG–
EKLRKIGQKI-KDFFGKLAPE-IEQ
43 [30]
CAP11b Guinea
pig
(GLRKKFRKTR–KRIQKLGRKI–
GKTGRKVWKA–WREYGQIPYY–
CRY)2
43 [31]
Fowlicidin-
1
Chicken RVKRVWPLVI–RTVIAGYNLY–
RAIKKK
26 [22]
Fowlicidin-
2
Chicken RVKRFWPLVP–VAINTVAAGI–
NLYKAIRRK
29 [22]
Fowlicidin-
3
Chicken LVQRGRFGRF–LRKIRRFRPK–
VTITIQGSAR-FG
32 [22]
rtCATH_1 Rainbow
trout
RRSKVRICSR–GKNCVSRPGV–
GSIIGRPGGG–SLIGRPGGGS–
VIGRPGGGSP–PGGGSFNDEF–
IRDHSDGNRF-A
71 [23,24]
rtCATH_2 Rainbow
Trout
RRGKDSGGPK–MGRKNSKGGW–
RGRPGSGSRP–GFGSGIAGAS–
GVNHVGTLPA–SNSTTHPLDN–
CKISP-Q
66 [24]
asCATH_1 Atlantic
Salmon
RRSQARKCSR–GNGGKIGSIR–
CRGGGTRLGG–GSLIGRLRVA–
LLLGVAPFLL–DLSQINVMEI–AFA
63 [24]
asCATH_2 Atlantic
salmon
RRGKPSGGSR–GSKMGSKDSK–
GGWRGRPGSG–SRPGFGSSIA–
GASGRDQGGT–RNA
53 [24]
HFIAP-1 Hagfish GFFKKAWRKV–KHAGRRVLDT–
AKGVGRHYVN–NWLNRYR
30 [25,49]
HFIAP-3 Hagfish GWFKKAWRKV–KNAGRRVLKG–
VGIHYGVGLI
30 [25,49]
In addition, the AMPs recently found in chicken and three species of fish are given.
a Two different studies reported two different sequences for a single
cathelicidin gene and the derived AMP, but agree that only one cathelicidin
gene is present.
b Homodimer via the C-terminal cysteine residue.A second cathelicidin holoprotein, denoted p15s, is found in
rabbit [37]. This holoprotein apparently does not undergo pro-
cessing with the release of an active AMP. Lehrer's group has
identified cathelicidins in goat. In addition to the publishedAMP
chBac5 [50], a homologue of bovine Bac5, they found three
other cathelicidins. These three sequences are deposited in the
GenBank database under the GI codes 5139355, 5139357, and
5139359, but no information is available on the mature AMPs.
2. Sources and function of LL-37
LL-37 and its precursor, hCAP18, are found at different
concentrations in very different cell and tissue types and body
fluids. This fact is closely related to its double nature as peptide
antibiotic and signaling molecule. The following paragraphs
describe the differential expression pattern and summarize the
current knowledge on LL-37's antimicrobial properties and its
signaling action.
2.1. Places of gene expression
LL-37 was first described in leukocytes and testis, but was
soon found in a large variety of cells, tissues and body fluids.
Table 2 summarizes the sites of expression that were described
for LL-37. The time-dependence of LL-37 gene expression in
maturing neutrophils has found special interest [53,54]. Bülow
et al. investigated the means by which immature hCAP18/LL-
37 is sorted for storage in specific granules [55]. LL-37, as well
as its proprotein, were also found bound to plasma lipoproteins
[36,56,57]. Sorensen et al. suggested that lipoproteins may form
an important reservoir for LL-37 [36]. Paulsen et al. did not find
LL-37 expression in the nasolacrimal duct [58].
Included in Table 2 are reports of increased or decreased LL-37
production in numerous diseases. Upregulation is found more
commonly than downregulation, indicating that LL-37 assists the
immune system in fighting disease. Bacterial products were
shown to increase LL-37 production in cultured sinus epithelial
cells [59]. Likewise, human beta-defensin-2 increases the level of
LL-37 expression in colon and breast epithelial cells [60]. In four
cases, decreased levels of LL-37 are found in disease. In atopic
dermatitis and chronic ulcers, this may be related to the causes of
the disease [61–63]. Pathogenic microbes may actively reduce
LL-37 production in enteric infection, thus ensuring their own
survival [64]. Patients suffering from morbus Kostmann are
devoid of LL-37 in granulocytes and saliva [65]. Unless treated
with cytokine G-CSF, all patients die from bacterial infections
within the first year of their life. Studies of xenograft models in
mice established a connection between LL-37 and cystic fibrosis
[66]. A recent review summarizes the role of LL-37 in lung
infection and inflammation [67].
2.2. Antimicrobial and cytotoxic activity
LL-37 was initially recognized for its antimicrobial proper-
ties [51,107–109]. It exhibits a broad spectrum of antimicrobial
activity against bacteria, fungi, and viral pathogens [70,75],
with microbicidal activity varying against different species and
Table 2
Various cell types and tissues where hCAP18/LL-37 expression was reported,
along with pathologies which are described to correlate with increased or
reduced expression of hCAP18/LL-37
Type of cell, tissue, or body fluid Reference
Leukocytes [34,35,68–70]
Myelocytes, metamyelocytes [70]
Bone marrow [32]
Breast milk [71,72]
Skin of newborn infants [73,74]
Numerous squamous epithelia [75]
Nail [76]
Sweat [77]
Wound fluid, blister fluid [78]
Ocular surface epithelia [79]
Synovial membranes [80]
Nasal mucosa [81]
Lung epithelia [82]
Developing lung [83]
Bronchoalveolar lavage fluid [84]
Salivary glands [85,86]
Saliva [85]
Gingiva [87]
Colon epithelium [88]
Colon mucosa [89]
Testis [32]
Epididymis epithelium, spermatozoa [90]
Seminal plasma [90,91]
Vernix caseosa [74,92–94]
Amniotic fluid [92,93]
Upregulation in disease
Keratinocytes in inflammatory disorders (psoriasis, lupus
erythematosus, contact dermatitis)
[95–97]
Gastric epithelia, H. pylori infection [98]
Inflamed synovial membranes [80]
Chronic nasal inflammatory disease [99]
Bronchoalveolar lavage fluid
In cystic fibrosis [100]
In sarcoidosis [84]
Tracheal aspirates of newborn infants [101]
Breast cancer [102]
Keratinocytes in condyloma acuminatum and verruca vulgaris [103]
Cholesteatoma [104]
Downregulation in disease
Atopic dermatitis [62,63]
Chronic ulcer epithelium [61]
Enteric infection [64]
Neutrophils, acute myeloid leukemia [105,106]
LL-37 is absent in granulocytes and saliva
Morbus Kostmann [65]
Table 3
Compilation of reported antimicrobial properties of LL-37
Organism LL-37 activity Reference
Gram positive bacteria
Streptococcus
Group A 1–16 μM [116]
Group B ≥32 μM [116]
Group C 16 μM [116]
Staphylococcus aureus N32 μM [116]
Enterococcus faecalis 30 μg/ml [82]
Staphylococcus epidermidis 7.6 μg/ml [107]
Listeria monocytogenes 1.5 μg/ml [107]
Enterococcus faecium 0.7 μg/ml [107]
Lactobacillus acidophilus 19 μM [28]
Bacillus subtilis 2.7 μg/ml [107]
Bacillus megaterium 0.2 μM [32]
Gram negative bacteria
Escherichia coli N32 μM [116]
Pseudomonas aeruginosa 16 μg/ml [82]
Actinobacillus actinomycetemcomitans 10 μg/ml [109]
Salmonella typhimurium 3.5 μg/ml [108]
Salmonella minnesota 0.2 μg/ml [108]
Burkholderia cepacia 79 μg/ml [107]
Capnocytophaga ochracea 11 μg/ml [109]
Klebsiella pneumoniae 4.2 μg/ml [108]
Proteus mirabilis 5.7 μg/ml [107]
Stenotrophomonas maltophilia 1.9 μg/ml [107]
Proteus vulgaris 2.5 μg/ml [107]
Capnocytophaga sputigena 7.5 μg/ml [109]
Capnocytophaga gingivalis 9 μg/ml [109]
Salmonella serovar dublin 2.8–6.0 μM [88]
Spirochaete
Leptospira interrogans 144–225 μg/ml [115]
Borrelia spp. 450 μg/ml [115,117]
Treponema pallidum 450 μg/ml [115,118]
Yeast
Candida albicans N20 μg/ml [108]
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published on a number of Gram positive and Gram negative
bacterial strains, as well as on the yeast Candida albicans. Anti-
viral action was investigated on two viruses. Only little viral
inactivation by LL-37 was reported for the herpes simplex virus
[110]. On the other hand, a reduction of virus replication was
found for the vaccinia (smallpox) virus [111].
ForCandida albicans, den Hertog et al. showed that the place
of action is the cell wall and cell membrane [112]. These showed
massive disruption in electron microscopy images. Remarkably,the same study found very different effects for the human AMP
histatin 5, namely minor membrane defects but intracellular
accumulation. López-García et al. found a correlation between
membrane permeabilization and C. albicans growth inhibition
[113]. In Bacillus subtilis, Pietiäinen et al. reported a complex
stress response when the organism was subjected to subinhib-
itory concentrations of LL-37 [114]. For a comparison of the
antimicrobial action of LL-37 with other human AMPs, readers
are referred to an article reported by De Smet and Contreras [7],
as well as on defensins by Dhople et al. in this special issue. The
study of Sambri et al. presented a comparison of LL-37 and four
other cathelicidin-derived AMPs with respect to their action
against three pathogenic species of spirochaetes (a special type
of bacteria showing flagellae and motility) [115].
Several studies reported the MIC values in high salt concen-
trations and under serum conditions, and found antimicrobial
action to be noticeably reduced [51,107,118,119]. Similarly, the
activity of LL-37 was reduced in the presence of a lung sur-
factant preparation [120] as well as in the presence of artificial
tears [121]. The loss of antimicrobial activity that is observed for
most AMPs in elevated salt concentrations, but is less
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relevant in diseases of the lung. High ionic concentrations are
generally found in body fluids of patients suffering from cystic
fibrosis and other inflammatory lung diseases. In this context,
gene transfer resulting in four-fold overexpression of LL-37 in a
cystic fibrosis xenograft model succeeded to restore bacterial
killing to normal levels [66], suggesting that LL-37 may protect
against bacterial lung infections and showing a possible
therapeutic strategy. Similarly, adenoviral gene therapy with
hCAP-18/LL-37 was found effective in the treatment of infected
burn wounds [122]. The reduced activity of LL-37 at high salt
levels made the in vivo relevance of LL-37's microbicidal action
disputable. However, Bals et al. [123] established a mouse
model whose properties were consistent with in vivo antimi-
crobial activity. Nizet et al. prepared knock-out mice in which
the gene coding for CRAMP, the mouse analogue of LL-37, was
disrupted [124,125]. These animals showed severely deteriorat-
ed resistance to necrotic skin infections caused by Group A
Streptococcus. In a later study, transgenic mice expressing the
porcine cathelicidin PR-39 in addition to CRAMP proved to be
better protected against bacterial skin infection [126]. Bowdish
et al. prepared an analog of LL-37 which lacked antimicrobial
activity, but which was still found to protect the mouse organism
from infection [127].
In cultured keratinocytes, Erdag et al. found expression of
antimicrobial peptides including LL-37 to be increased after
application of interleukin-1α and interleukin-6, and found the
treated tissue to be better protected against three bacterial species
[128]. In gastrointestinal cells, LL-37 expression was induced by
histone-deacetylase inhibitors [129]. In colonocytes, LL-37
expression is modulated by short chain fatty acids [130].
A number of studies described bacterial strategies to counter
antimicrobial peptides. Bacteria of the upper respiratory tract were
able to evade the antibacterial action of LL-37 by increasing the
amount of phosphatidylcholine lipids in their membranes [131].
Similarly, the polysaccharide intercellular adhesin (PIA) joining
Staphylococcus epidermidis into biofilms was shown to protect
the bacterium from LL-37 action [132]. Common pathogenic
bacteria inactivate LL-37 by degradation through proteinases
[132–135]. In the case of Pseudomonas aeruginosa, Werthén et
al. showed that a synthetic cationic polymer was able to inhibit
these proteinases [136]. In addition to protecting proteinases,
Streptococcus pyogenes also excretes a protein that interacts with
the complement system and was additionally found to interfere
with LL-37 action [137,138]. McPhee et al. described a two
component regulatory system that regulates resistance in Pseu-
domonas aeruginosa [139]. Shafer et al. reported that an efflux
pump effectively protects Neisseria gonorhoeae from the lethal
action of LL-37 and protegrin-1 [140].
Decreased levels of LL-37 were found in enteric infection,
possibly indicating a downregulation in expression that is caused
by the invading pathogens [64]. Similarly, a downregulation of
LL-37 in Neisseria gonorrhoeae infection was described by
Bergman et al. [141]. Tzeng et al. investigated causes for the
intrinsically high resistance of Neisseria meningitidis against
cationic antimicrobial peptides, including LL-37 [142]. Samuel-
sen et al. found that strains of Staphylococcus aureus that haddeveloped resistance to lactoferricin B showed related cross-re-
sistance to other antimicrobial peptides, but not to LL-37 [143].
The in vitro cytotoxicity of LL-37 was addressed in two
studies. Johansson et al. found LL-37 concentrations of 13–
25 μM to be sufficient to make human leukocytes and T-cells
nonviable [51]. Oren et al. found substantial lysis of red blood
cells at similar concentrations of LL-37 [144]. These concentra-
tions are surprisingly similar to the MIC values collected in
Table 3 and characterize LL-37 as a comparatively unspecific
antimicrobial agent, whichmight as well be referred to as a toxin.
Synergistic action between LL-37, β-defensins, and lysozyme
was initially described by Nagaoka et al. [145] and later com-
prehensively investigated by Chen et al. [146] Evaluation of their
combined action against E. coli and S. aureus in neutral as well as
acidic milieus was performed. The synergistic effect found was
strong enough to make the authors speculate that defensins may
not be able to act as antibacterial molecules by themselves, but
only in synergism with cathelicidins [145]. However, Singh et al.
found only additive action when investigating LL-37 in com-
bination with other antimicrobial peptides of the human airway
surface liquid [147].
All of the studies on antimicrobial activity published to date
used peptide prepared by solid-state synthesis. Only recently two
groups developed vectors for expression of recombinant peptide
in E. coli. Li et al. expressed the wild type sequence [148], while
Yang et al. expressed GSLL-39 [149], a slightly elongated variant
of LL-37 that showed identical antimicrobial properties. In our
laboratory, we have successfully expressed and purified LL-37
from E. coli [150]. For details on the biological expression and
purification, we refer to the article by Moon et al. in this special
issue.
2.3. Lipopolysaccharide binding properties
From the point of its discovery, investigators also realized that
LL-37 shows a strong binding affinity for lipopolysaccharides
(LPS) [33,34,107]. This property is also known for rabbit CAP18
[151], and is physiologically relevant since LPS form the outer-
most membrane leaflet of Gram-negative bacteria. Released from
those bacteria in sepsis, LPS is termed ‘endotoxin’ and causes
adverse effects like septic shock by inducing the production of
higher concentration of systemic pro-inflammatory cytokines.
However, LL-37 can neutralize the biological activity of LPS by
binding it with higher affinity [33,152–155]. Herasimenka et al.
investigated the binding behavior of LL-37 with LPS from three
lung pathogens [156]. By comparing LL-37 to three other AMPs,
Rosenfeld et al. established a positive correlation between binding
affinity and a peptide's ability to inhibit LPS-induced cytokine
secretion [157]. Likewise, Zughaier et al. found LPS-induced
macrophages to secrete markedly less tumor necrosis factor α
(TNF-α) as well as reactive oxygen species (ROS) in the presence
of LL-37 [158]. Bowdish et al. showed that LL-37 and indolicidin
synergistically suppress LPS-induced secretion of TNF-α from
macrophage cell lines [159]. Ciornei et al. investigated rat aorta in
vivo and measured reduced production of nitric oxide in the
presence of LL-37 [160]. Two studies addressed the structure of
LPS-binding peptides: an NMR structure is available for sheep
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from horseshoe crab [162]. Nagaoka et al. performed mutation
studies to enhance the LPS-binding effect on mutated analogs of
LL-37 [163]. By changing the hydrophobicity and cationic prop-
erties of an 18-mer peptide (K15 to V32), they were able to
increment its ability to neutralize LPS. An in vivo study by
Fukumoto et al. applied LL-37 to rats inwhich sepsis was induced
by exposure to peritoneal LPS injection [164]. The study showed
that LL-37 improved the course of sepsis, which can be explained
by retained LPS-binding in vivo. However, the same study found
higher doses of LL-37 to have adversary effects on the survival
rates of the test animals, possibly related to the cytotoxic prop-
erties of LL-37.
2.4. Chemotactic activity of LL-37
Chertov et al. found LL-37 to chemoattract T-cell leukocytes
[165], as well as mononuclear cells and neutrophils [166]. In
addition, interleukin-8-stimulated neutrophils were found to re-
lease LL-37 [165], thus attracting evenmore leukocytes to sites of
increased LL-37 concentration. As described above, increased
levels of LL-37 are regularly found in inflamed or infected tissue.
Interestingly, the chemotactic activity of LL-37 is not affected by
the presence of serum [167], at the same serum concentrations that
are known to inhibit its in vitro antimicrobial effects [51,107].
Dendritic cells form another class of leukocytes receptive to LL-
37. Davidson et al. found LL-37 to profoundly influence the exact
course of their maturation process, a process which forms the
borderline between innate and adaptive immunity [168]. Scott et
al. treated mice with intratracheal application of LL-37 and found
increased production of the chemokineMCP-1, but no increase in
the inflammatory mediator TNF-α [152]. They interpret this as
evidence that LL-37 can block bacterial product-induced inflam-
mation while simultaneously recruiting macrophages.
Mast cells, which form an important tissue-localized part of
innate immunity, show degranulation upon stimulation with LL-
37 [169]. Degranulation releases pro-inflammatory mediators,
such as histamine and prostaglandins, into the surrounding tis-
sue, thus increasing vascular permeabilization and promoting
the infiltration of inflammatory cells. In addition, mast cell
migration is induced by LL-37 [170]. Di Nardo et al. found that
mast cells are not only susceptible to LL-37, but also produce the
peptide themselves [171]. The effects of LL-37 on mast cells
were reviewed by Niyonsaba et al. [172].
The signaling means by which LL-37 exerts its immunos-
timulatory effects are presently a very active and productive area
of research. LL-37 was proven to activate at least three different
receptors, namely FPRL-1 (formyl peptide receptor-like 1)
[167,173], EGFR (epidermal growth factor receptor) [174], and
P2X7 [175]. For both FPRL-1 and P2X7, a direct activation via
specific binding is postulated, while for EGFR only transactiva-
tion was discussed. EGFRwas found to be activated by the all-D
analog of LL-37 [176]. This activation is stronger than the one
by the wild type, probably due to increased resistance to
proteolytic degradation. Likewise, LL-37 induces activation of
extracellular signal-regulated kinase and p38 kinase signaling
pathways in monocytes [177] and keratinocytes [178]. In aconfocal microscopy study performed on fluorescently labeled
LL-37, the peptide was found to be actively taken up into lung
epithelial cells and trafficked to their perinuclear region [179].
This is in contrast to the situation in the target organismCandida
albicans, where LL-37 could not be detected in the cytoplasm
[112]. Bowdish et al. give an in-depth description of the detailed
mechanisms of the immunostimulatory effects of LL-37 [127].
Lau et al. demonstrated that LL-37 induces apoptosis in cultured
lung and airway epithelial cells, and in vivo in the murine airway
[180]. Using cultured cells, LL-37 was shown to bind DNA
plasmids and to target them to the cell nucleus in membrane raft
dependent endocytosis [181].
2.5. Role of LL-37 in wound healing and angiogenesis
Increased levels of LL-37 were found in human skin after a
wound had been inflicted [116], which returned to normal
levels as the wound closed. A later study found re-forming
epithelium migrating over the wound bed to be the primary
place of LL-37 expression in wounds [61]. The same study
found that inhibition of LL-37 by specific antibodies prevented
wounds from healing, and found reduced levels of LL-37 in
chronic ulcer epithelium. Other studies found LL-37 production
to be increased by common growth factors [182], or suggest
that LL-37 acts as a putative growth factor for epithelial cells
[102]. Tokumaru et al. [183] showed that LL-37 induces the
migration of keratinocytes, and established a connection to the
transactivation of epidermal growth factor receptor. A review
article by Borregaard et al. [184] stresses the necessity to
coordinate the behavior of neutrophils and keratinocytes in
wound healing, and the role that LL-37 plays as a signaling
molecule in that context. Shaykhiev et al. found a similar
stimulation for airway epithelial cells in the presence of LL-37
[185].
Angiogenesis is another interesting function of LL-37. Koc-
zulla et al. found that application of LL-37 resulted in neovas-
cularization in a tissue model as well as in a rabbit model [186].
Moreover, they showed the receptor FPRL-1 on endothelial cells
to be the mediator of angiogenesis. An angiogenic role is also
described for a cathelicidin-derived AMP in pig [187]. Remark-
ably, the porcine peptide is not a member of the α-helical class of
AMPs.
3. Structural studies on LL-37
3.1. Amphipathic properties
The primary structure of LL-37, LLGDF–FRKSK–EKIGK–
EFKRI–VQRIK–DFLRN–LVPRT-ES, was given along with
other α-helical cathelicidin-derived antimicrobial peptides in
Table 1. The sequence reveals the highly charged nature of the
peptide. At physiological pH, 16 of its 37 residues are charged,
namely 6 Lys and 5 Arg residues carry 11 positive charges, while
3 Glu and 2 Asp residues bear 5 negative charges. The resulting
net charge at physiological pH is + 6. LL-37 assumes an α-helical
secondary structure under physiological conditions. This behav-
ior is found in all species that have a single cathelicidin. All
Fig. 2. Helical wheel projections of the cathelicidin-derived AMPs from species that are known to possess only a single cathelicidin. They are found in (top left to
bottom right) human, rhesus monkey, rabbit, mouse, rat, and guinea pig. For sequences and references, see Table 1. Positively charged (blue), negatively charged (red),
polar (white), and hydrophobic (gray) residues are highlighted.
Fig. 3. A hypothetical ideal α-helical structure of LL-37. Surface representation
and cartoon sketch for illustrating amphipathic properties. Note that the N-
terminal region (right end) does not readily form an amphipathic α-helix.
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the same set of six AMPs, Fig. 2 gives the helical wheel
projections. The projections show that all six peptides gain
striking amphipathic features when assuming a helical structure.
Amphipathicity is common to all antimicrobial peptides and
allows them to interact electrostatically with anionic bacterial
membranes. In each helical wheel diagram of Fig. 2, the hydro-
phobic residues (shaded gray) cluster in a certain portion of the
helix perimeter. The charged and polar residues (shaded red, blue
and white for negatively charged, positively charged, and polar
residues, respectively) populate the opposite face of the helix. All
six peptides show a ‘hydrophobic angle’ of approximately 160° of
the helix circumference.A closer inspection of the human peptide,
LL-37, reveals that in the N-terminal region, the amphipathic
faces of the helix are less perfectly formed. This suggests that the
N-terminus is less apt to form α-helical secondary structure, thus
explaining the 20–30% random coil proportion found in CD
spectroscopy (see next section).
Although CAP11 was shown to form covalently bound ho-
modimers via its C-terminal cysteine residues, it still displays a
strikingly similar helical wheel when compared to other peptides
in Fig. 2. This indicates that CAP11's covalent dimer structure
does not make it an exception. Instead, a non-covalent dimer-
ization may be expected as an important common feature that is
yet to be discovered in other systems.Fig. 3 gives a three-dimensional model of the peptide in an
assumed perfect α-helical conformation. The C-terminal region
forms an aliphatic α-helix, which is the major recurring structural
motif present in all known α-helical AMPs. This amphiphilic
pattern does not extend through the whole molecule. Rather, the
N-terminal region consists of stretches of hydophilic and hydro-
phobic residues, which close to form two “rings” or “strips”
around the N-terminus (assuming this terminus is α-helical in
structure). The cartoon representation shown in the lower half of
Fig. 3 tries to capture this very abstract description of hydrophobic
properties. A closer examination of the three-dimensional model
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imity. There are more pairs of oppositely charged residues, which
are energetically favorable and may form salt bridges, than there
are energetically unfavorable pairs of equally charged residues.
The geometrical distribution of amphiphilic properties is repre-
sented very clearly in the ‘helical net diagram’ given as Fig. 1 of
Johansson et al. [51].
3.2. Studies using circular dichroism spectroscopy
Initial CD spectroscopic studies were conducted in connection
with the respective functional studies [32,107]. It was found that
LL-37 is in random-coil conformation in pure aqueous solution,
but adopts partly helical secondary structure in common structure-
inducing environments [51,150]. These include trifluoroethanol
and the presence of salts or lipid bilayer vesicles. In most studies,
LL-37 was found to be only 70–80% α-helical, in good agree-
ment with the more hydrophobic nature of the N-terminus, which
cannot readily form an amphipathic helix.
The study of Johansson et al. [51] is the most comprehensive
among CD spectroscopic work. Here, positively charged ions
present in aqueous solution were found to be more apt to induce
α-helical secondary structure than negative ions. In addition,
antimicrobial testing was performed at the same conditions that
were used for CD spectroscopy. It was found that conditions
promoting α-helical structure are also making the peptide more
effective in killing bacteria. Moreover, human serum was found
to reduce the antimicrobial activity of L-37. Johansson et al.
[51] observed cooperative behavior in CD experiments, indi-
cating that α-helical LL-37 forms tetramers and even higher
oligomers in solution. Oren et al. [144] confirmed this finding
by chemical cross-linking in solution that proved the presence
of dimers, trimers, and higher oligomers in a concentration-
dependent distribution. This propensity of LL-37 to form
α-helical aggregates in aqueous solution can be rationalized by
the Hofmeister effect [188]. Here, the increasing ionic strength
of the solvent makes it more and more unfavorable for the
peptide to expose hydrophobic faces. Thus, an increasing salt
concentration causes the peptide to form increasing amounts of
secondary structure, to favor oligomeric assemblies where
hydrophobic faces are hidden, and eventually to precipitate. The
Hofmeister effect is commonly employed in processing of
proteins, where precipitates are generated by “salting out” the
protein. The Hofmeister effect as the driving force for LL-37
aggregation in the presence of salt is supported by the study of
fragments of LL-37 lacking the hydrophobic N-terminus (see
Section 3.5 below). These do not form α-helical structure in
solution (unpublished data from our laboratory).
LL-37's properties to assume a secondary structure and form
oligomers in aqueous solution is different from the ordinary
behavior found in antimicrobial peptides, which typically as-
sume a secondary structure only upon membrane binding [189].
Thus, the energetical advantage of forming a secondary structure
upon binding may not be present in LL-37, hence LL-37 should
bind less readily to membranes. So far, we described studies that
were performed in aqueous or buffer solution. Next, we will
discuss studies in the presence of lipid bilayers.3.3. Behavior in model lipid membranes/vesicles
Oren et al. [144] employed the fluorescent properties of rho-
damine- and NBD-labeled LL-37 analogs along with a number of
other biophysical techniques to studyLL-37 in zwitterionic POPC
vesicles as well as in charged POPS/POPC vesicles. LL-37 was
found to readily bind to the surface of both types of vesicles, and
to induce comparative leakage in both vesicles. This is seen in
close correlation with the comparable hemolytic and antimicro-
bial properties. In contrast, a study by Neville et al. [190] on lipid
monolayers found LL-37 to insert into and disrupt DPPG mono-
layers, but to have virtually no effect on DPPC and DPPE
monolayers. Using FTIR spectroscopy, Oren et al. [144] found
that membrane-bound LL-37 has 85% α-helical content, while a
small β-sheet or extended contribution was also reported. Po-
larized ATF-FTIR spectroscopy showed that the peptide lies on
the membrane surface, thus giving no indication of a pore-
formingmechanism of antimicrobial action as suggested by solid-
state NMR experiments (see below).
Finally, fluorescence and FRET experiments indicated that
LL-37 forms dimers or higher oligomers in zwitterionic POPC
vesicles, while being monomeric in anionic POPC/POPS vesicles
[144]. This oligomer formation in membrane environment is
different from the aggregation reported for LL-37 in aqueous
solution. There, the highly hydrophobic N-terminus of the peptide
is thought to drive the formation of oligomeric aggregates based
on physicochemical principles. In a membrane environment,
however, this line of reasoning no longer holds true. Conse-
quently, and considering the differing behavior in zwitterionic and
charged membranes, the formation of membrane-associated
oligomers is likely to bear functional significance.
The flat alignment of LL-37 on the surface of the lipid
bilayer does not preclude the possibility of a dimer formation.
Since the axial rotation of the peptide is not well characterized at
present, it may align its hydrophobic profile monomerically
with the hydrophobic properties of the lipid bilayer, as
suggested by Oren et al. [144]. It may equally well form a
dimer and insert as such into the hydrophilic headgroup region
of the lipid bilayer, as reported for Magainin2 [191,192] and
PGLa [193].
3.4. Studies using nuclear magnetic resonance spectroscopy
While studies on the three-dimensional structure determina-
tion of LL-37 are in progress in our laboratory, a structure of the
corresponding CAP18-derived AMP in rabbit was determined
using solution NMR experiments [52]. Since this structure was
obtained in a strongly helix-inducing environment, namely 30%
TFE solution, the resulting monomeric and fully α-helical
structure does not carry any physiological meaning.
Our laboratory has conducted extensive solid-state NMR
structural studies of LL-37 in model lipid bilayers [194]. LL-37
was synthesized with three isotope labels incorporated into the
peptide backbone for the solid-state NMR experiments. Two
carbon-13 nuclei were introduced in the carbonyl position of
Leu-31, and into the Cα-position of Ala-13. Labeling of
chemically distinct positions allowed for immediate assignment
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observed for both labels showed the peptide to have α-helical
structure in those positions, indicating that the α-helical region
of the peptide extends at least from residue 13 to 31. A single
nitrogen-15 isotope label in the amide group of Val-21 allowed
the determination of the peptide's orientation within macro-
scopically aligned DMPC bilayer samples. It turned out that the
helical part of the peptide lies on the bilayer surface, forming an
angle of about 72° between the helical axis and the bilayer
normal. A 1D dipolar shift experiment confirmed this result,
which is also in agreement with the ATR-FTIR experiment of
Oren et al. [144]. A 2D PISEMA experiment was performed and
the measured 1H–15N dipolar coupling was in agreement with
these results. Since a transmembrane orientation of the peptide was
not observed for concentrations up to 7 mol% in our studies, the
barrel-stave mechanism of membrane-disruption by the peptide
can be ruled out [194].
In subsequent experiments, Henzler-Wildman et al. investi-
gated the effect of temperature, peptide concentration, lipid com-
position, and the presence of ions onto LL-37's orientation [194].
Only minor changes were observed. In addition, 31P-NMR was
used to investigate the peptide-induced disorder on the lipid
bilayer. In a variety of model bilayers as well as in E. coli lipids,
LL-37 interactions with membranes have been very well char-
acterized. Both solid-state NMR and differential scanning cal-
orimetry (DSC) experiments suggested that perturbation is
effected by the induction of positive curvature strain on lipid
bilayers, which stabilizes non-lamellar phases, but was not found
to cause isotropic phases such as micelles or cubic phase. This
suggests that the peptide is immobilized in bilayers. The as-
sumption of an immobilized peptide is in good agreement with the
measured 1H–15N dipolar coupling from 15N-labeled LL-37
using PISEMA (polarization inversion spin exchange at themagic
angle) [195–197] experiments (unpublished) and 2H quadrupole
couplings from 2H-labeled LL-37 embedded in multilamellar
vesicles. In a consecutive study, Henzler-Wildman et al. [198]
investigated the effect the peptide takes onto the hydrophobic core
of the lipid bilayer. In DSC experiments, it was found that LL-37
suppresses the pre-transition in DMPC and DMPC:DMPGmem-Fig. 4. Membrane-bound LL-37 resides in the bilayer interface region. Solid-state N
The plot shows the helical wheel projection of the central region of LL-37 in the mem
the cartoon tries to capture the disorder that the peptide induces in the lipid acyl chai
ordered acyl chains in the absence of lipid (left) [198].branes, and makes the main phase transition less cooperative. The
asymmetric shape of thermograms observed at a high LL-37
concentration may indicate the presence of peptide-rich and pep-
tide-poor bilayer domains, as observed for PGLa [199,200] and
pardaxin [201,202]. Solid-state 2H-NMR experiments on chain-
deuterated lipids enabled the measurement of the acyl-chain order
parameter profiles in the presence of LL-37. Analyzing the order
parameter profiles using the first-order mean-torque model, mate-
rial properties of the lipid bilayer were extracted [150,198]. In
summary, it was found that LL-37 disrupts acyl-chain packing
and cooperativity. It inserts into the hydrophobic–hydrophilic
interface of the bilayer. This insertion is sensitive to the lipid
composition of the investigated bilayer. Cholesterol, a highly
abundant component in mammalian membranes, was found to
reduce the peptide-induced disorder in the membrane bilayer.
Since cholesterol is known to make the bilayer rigid, the peptide-
induced disorder particularly in the hydrophobic core of the
bilayer is suppressed [198]. In summary, the solid-state NMR
studies rule out the barrel-stave mechanism, the detergent-like
mechanism of bilayer disruption, and the induction of non-
lamellar phases such as hexagonal or cubic phases. Further, these
results suggest a carpet/toroidal-type model to explain LL-37
action. A cartoon summarizing the structural findings of solid-
state NMR and DSC experiments is given in Fig. 4.
3.5. Truncation and mutation studies
An increasing number of studies focus on the properties of
fragments of LL-37. A fragment is usually denoted by the one-
letter-code abbreviations of its two initial amino acids, followed
by the number of residues it is composed of. Consider, as an
example, a fragment lacking the initial eight residues in the N-
terminus. Its sequence starts with the amino acids serine and
lysine and consists of 29 amino acid residues. Therefore, its
shorthand notation is SK-29. Increased antibacterial action was
found for three cleaved fragments of LL-37 present in human
sweat [42], as mentioned above. Johansson et al. [51], along
with their studies of the wildtype peptide, investigated the two
truncated variants FF-33 and SK-29. These lack 4 and 8 residuesMR experiments show that the peptide lies on the membrane surface [150,194].
brane interface and aligned according to its amphiphilic properties. In addition,
n region as measured in 2H solid-state NMR experiments, as compared to more
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hydrophilic than the full-length peptide. Both fragments formed
α-helices less readily in aqueous solution and were less
effective in killing bacteria. Oren et al. [144] also worked on
FF-33 in addition to LL-37, and found FF-33 to have identical
antimicrobial properties, but two-fold less hemolytic potential.
Moreover, they find that FF-33 does not dimerize in zwitterionic
membranes and is far less effective in making these membranes
permeable. They interpret this behavior as the reason for FF-
33's reduced hemolytic activity. Isogai et al. [203,204] inves-
tigated the peptide fragment FR-27 as well as two mutants with
increased hydrophobicity. They found increased antimicrobial
activity and increased LPS-binding affinity in all their frag-
ments. Remarkably, in a later study Okumura et al. [205] found
that carcinoma cells from oral squamous cells undergo apo-
ptosis when exposed to the fragment FR-27 and its two mutants.
This does not happen in healthy cells, showing a possible way
for a future therapeutic strategy. Nagaoka et al. investigated the
antimicrobial [206] and LPS-binding [163] properties of the 18-
mer fragment KE-18. In addition, they prepared two mutants
with increased hydrophobic angle and increased polarity in the
hydrophilic face. They found similar or increased antibacterial
activity, marked hemolytic potential, and improved binding to
LPS. Ciornei et al. [207] extended those studies to the fragments
RK-31 and GD-35. While those fragments showed reduced
hemolytic potential, the antimicrobially most potent mutant of
KE-18 induced severe hemolysis.
Andersson et al. [208] found that structural motifs with
heparin-binding affinity may confer antimicrobial properties to a
peptide. The most comprehensive set of fragments was inves-
tigated by Braff et al. [176]. They prepared 14 different frag-
ments as well as the wildtype peptide and its all-D analog. The
declared aim was to identify the regions that are involved in
immunostimulatory signaling, and to distinguish them from the
regions responsible for antimicrobial action. The fragments KS-
30 and RK-31 showed highest (increased) antimicrobial activity,
while truncation of the central fragment EK-20 led to a sharp
decline in antimicrobial activity. Antimicrobial activity did not
correlate with stimulated IL-8 release from keratinocytes. On the
contrary, immunostimulatory properties seem to reside in the N-
terminal region of the peptide, which does not form an amphi-
philicα-helix (see Fig. 3), while antimicrobial action seems to be
borne by the amphiphilic C-terminal α-helix. Nell et al. prepared
an equally comprehensive set of analogs, with the aim of finding
the optimal fragment for pharmaceutical application [209]. In a
mutant of the fragment IG-22, they find optimal antibacterial and
LPS-binding properties at lower pro-inflammatory and cytotox-
ic activity. A far more complex genetic construct was used in
a study by An et al. [210]. LL-37 was genetically fused to a
receptor gene and the resulting construct was found to protect
mice from challenges with tumor cells.
In our laboratory, we have synthesized a 21-residue amphi-
pathic helical fragment (called RK-21) of LL-37. Structural and
functional studies on this peptide have been completed (unpub-
lished). This peptide does not form a helical structure in solution
but forms a helical structure in a membrane environment. It has
been shown to have a broad spectrum of antimicrobial activityand better selectivity than the native peptide. Hence, it seems to
bear greater similarity with other antimicrobial peptides that
form secondary structure only upon membrane interaction, de-
pending on the composition of the targeted membrane.
4. Summary and outlook
Today, an increasingly complete picture of the role of human
antimicrobial peptides keeps emerging. In human, as well as in
all investigated mammalian organisms, antimicrobial peptides
fill two clearly distinct roles. On the one hand, they show
antimicrobial activity and are constitutively expressed in skin
and epithelia to protect these covering tissues from invading
bacteria. They are additionally utilized by white blood cells for
the direct killing of microbes, and may help alleviate sepsis by
their LPS-binding propensity. In a second, completely different
role, they fill functions as signaling molecules on the borderline
of innate and acquired immunity.
LL-37 is a specific human antimicrobial peptide for which all
the aspects as mentioned above in a general context fully apply.
LL-37 is the only representative of the class of cathelicidin-derived
AMPs that is found in human. This review article has given an
overview about the current knowledge of its antibiotic as well as
immunoregulatory roles. Also, studies on the gene of the precursor
cathelicidin protein, and the connected regulation of expression
have been thoroughly mentioned. Studies on the cathelicidins of a
number of species allows for phylogenetic comparison between
these species. In summary, a large and ever-increasing amount of
knowledge exists on the genetics and the antibiotic and immuno-
regulatory roles of LL-37. In contrast, insight into its structure is
still very limited and relying on only a handful of studies. In lipid
environment, LL-37 assumesα-helical structure and binds periph-
erally to the membrane. This is analogous to most other α-helical
antimicrobial peptides. In zwitterionicmembranes, LL-37 is found
in oligomeric form.Our solutionNMRexperiments suggested that
LL-37 behaves like a ∼ 30 kDa protein in size due to oligo-
merization (data unpublished). Our 14N (unpublished results) and
PISEMA [195–198] solid-state NMR experiments on aligned
bilayers containing LL-37 suggest that the oligomerization of the
peptide depends on the composition of themembrane. Fig. 5 gives
a graphical overview about the structural properties known for LL-
37 in solution and lipid bilayer environments.
The formation of oligomers seems to be a recurring theme in
the action of antimicrobial peptides [191–193,198,211,212]. In
the case of LL-37 it could be speculated that the reported
activation of three membrane receptor systems may be closely
related to a dimer formation. Future solid-state NMR spectro-
scopic studies on selectively or uniformly isotope labeled LL-37
may help to further characterize the oligomeric state of LL-37 in
solution and in lipid bilayers. The aptitude of the isotopic label-
ing scheme will be of critical importance for the success of such
studies, since a vast multitude of oligomeric states can be readily
imagined already for hypothetical dimers. Fig. 6 gives an illus-
tration of the potential contribution that advanced methods of
solid-state NMR can make to the structural characterization of
LL-37 in lipid bilayers. The figure shows simulated PISEMA
spectra of uniformly 15N-labeled LL-37 in lipid bilayers aligned
Fig. 5. A graphical summary of LL-37 folding in solution and membrane environments. In aqueous solution, LL-37 readily forms α-helical secondary structure and
assembles into oligomers (top). It is not known whether binding to lipid bilayers proceeds via unordered, ordered or oligomerized structures. LL-37 binds readily to
lipid bilayers, in zwitterionic bilayers it is reported to form oligomers, possibly dimers (middle). Mechanism of antibacterial action is illustrated in Fig. 4
[150,194,198]. A barrel-stave mechanism of action (bottom right) was ruled out by solid-state NMR experiments on aligned bilayers, leaving the carpet model (left) or
a toroidal-type model to explain LL-37 action.
1419U.H.N. Dürr et al. / Biochimica et Biophysica Acta 1758 (2006) 1408–1425with the bilayer normal parallel to the external magnetic field of
the spectrometer. The two spectra shownwere calculated for two
orientations of the molecule with respect to the magnetic field.Fig. 6. 15N-PISEMA spectra simulated for a hypothetical molecular model of LL-37
into a random conformation. The molecular models are shown as inset, the directio
external magnetic field, B0. (Left) Spectrum calculated for a membrane surface-attach
calculated for a transmembrane orientation of the peptide in the lipid bilayer. Note tha
in the lower portion of Fig. 5. Spectra were calculated using the SIMMOL simulatiThe SIMMOL simulation package was used for the calculations
[213]. The markedly different resonance patterns observed for
both cases demonstrate the wealth of structural information thatin which the C-terminal region is α-helical, while the N-terminus was distorted
n of the membrane normal was assumed to be identical to the direction of the
ed orientation as found by Henzler-Wildman et al. [150,194]. (Right) Spectrum
t the spectra correspond to the concurring models of antimicrobial action shown
on package [213].
1420 U.H.N. Dürr et al. / Biochimica et Biophysica Acta 1758 (2006) 1408–1425is present in each PISEMA spectrum. With the availability of
recombinant LL-37 (see the study by Moon et al. in this issue),
these solid-state NMR experiments are now feasible.
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